Published in Clin Gastroenterol Hepatol on November 01, 2005
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol (2013) 3.25
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
HCV and oxidative stress in the liver. Viruses (2013) 1.28
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Ethanol prevents development of destructive arthritis. Proc Natl Acad Sci U S A (2006) 1.18
Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08
Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08
National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009. Drug Alcohol Depend (2014) 1.02
Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health (2009) 0.96
Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One (2012) 0.88
Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease. BMJ Open (2015) 0.87
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res (2013) 0.84
Chronic ethanol diet increases regulatory T-cell activity and inhibits hepatitis C virus core-specific cellular immune responses in mice. Hepatol Res (2013) 0.84
Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol (2014) 0.82
Update on Alcohol and Viral Hepatitis. J Clin Transl Hepatol (2014) 0.81
Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep (2010) 0.80
Alcoholic liver disease and hepatitis C virus infection. World J Gastroenterol (2016) 0.79
Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. Drug Alcohol Depend (2014) 0.79
Correlates of hazardous drinking among Veterans with and without hepatitis C. J Behav Med (2012) 0.79
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res (2016) 0.78
Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy? BMC Infect Dis (2014) 0.77
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res (2010) 0.77
Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat (2015) 0.76
Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog (2017) 0.75
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med (2016) 0.75
Moderate Alcohol Use and Insulin Action in Chronic Hepatitis C Infection. Dig Dis Sci (2016) 0.75
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug Alcohol Depend (2016) 0.75
Alcohol consumption in patients with primary sclerosing cholangitis. World J Gastroenterol (2012) 0.75
A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. BMC Infect Dis (2016) 0.75
Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. Am J Drug Alcohol Abuse (2015) 0.75
Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Curr Hepatol Rep (2017) 0.75
Positive CAGE screen correlates with cirrhosis in veterans with chronic hepatitis C. Dig Dis Sci (2007) 0.75
Meta-analysis of drug-related deaths soon after release from prison. Addiction (2010) 3.96
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
18 years of the Fontan operation at a single institution: results from 771 consecutive patients. J Am Coll Cardiol (2012) 2.24
Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology (2005) 1.91
A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996-2006. Addiction (2012) 1.88
Incomplete contingency tables with censored cells with application to estimating the number of people who inject drugs in Scotland. Stat Med (2013) 1.74
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology (2011) 1.68
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol (2012) 1.62
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis (2013) 1.61
High-fluence and high-density treatment of perioral rhytides using a new, fractionated 2,790-nm ablative erbium-doped Yttrium Scandium Gallium Garnet Laser. Dermatol Surg (2011) 1.60
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Outcomes of Single-Ventricle Patients Supported With Extracorporeal Membrane Oxygenation. Pediatr Crit Care Med (2016) 1.42
Buried data and the UK Healthcare Commission's legacy. Lancet (2009) 1.39
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
A multistep approach to improving biopsy site identification in dermatology: physician, staff, and patient roles based on a Delphi consensus. JAMA Dermatol (2014) 1.37
Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial. J Urban Health (2013) 1.34
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One (2013) 1.32
Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates. Addict Res Theory (2012) 1.29
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.23
Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery. Pediatr Cardiol (2012) 1.18
Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23,183 individuals. Addiction (2009) 1.18
Nd:YAG laser (1064 nm) irradiation for lower extremity telangiectases and small reticular veins: efficacy as measured by vessel color and size. Dermatol Surg (2002) 1.17
Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture--recapture methods. Stat Methods Med Res (2008) 1.12
A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg (2004) 1.07
Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. Int J Drug Policy (2011) 1.05
Prior information in behavioral capture-recapture methods: demographic influences on drug injectors' propensity to be listed in data sources and their drug-related mortality. Am J Epidemiol (2005) 1.03
A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res (2008) 1.03
The use of photodynamic therapy in dermatology: results of a consensus conference. J Drugs Dermatol (2006) 1.03
Radiofrequency in cosmetic dermatology: a review. Dermatol Surg (2012) 1.00
Dermal fillers: complications and informed consent. J Cosmet Laser Ther (2005) 1.00
Topical anesthetics for cosmetic and laser dermatology. J Drugs Dermatol (2005) 0.99
Failure of the fontan circulation. Heart Fail Clin (2014) 0.99
Mesotherapy for facial skin rejuvenation: a clinical, histologic, and electron microscopic evaluation. Dermatol Surg (2006) 0.98
Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther (2004) 0.98
Extraocular sebaceous carcinoma treated with Mohs micrographic surgery: report of a case and review of literature. Dermatol Surg (2007) 0.97
Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy (2012) 0.95
Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohistochemical analysis. Dermatol Surg (2008) 0.95
Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol (2012) 0.94
Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol (2007) 0.94
Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol (2012) 0.94
Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01. Lancet (2003) 0.93
Atrophic and a mixed pattern of acne scars improved with a 1320-nm Nd:YAG laser. Dermatol Surg (2003) 0.93
Anthrax infection among heroin users in Scotland during 2009-2010: a case-control study by linkage to a national drug treatment database. Clin Infect Dis (2012) 0.93
Laser lipolysis of the arm, with and without suction aspiration: clinical and histologic changes. J Cosmet Laser Ther (2009) 0.93
Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. Emerg Infect Dis (2013) 0.93
Ultrastructural changes seen after ALA-IPL photorejuvenation: a pilot study. J Cosmet Laser Ther (2005) 0.92
How do centres begin the process to prevent contrast-induced acute kidney injury: a report from a new regional collaborative. BMJ Qual Saf (2011) 0.91
A prospective study of fractional scanned nonsequential carbon dioxide laser resurfacing: a clinical and histopathologic evaluation. Dermatol Surg (2009) 0.90
Clinical, histologic, and ultrastructural changes after use of human growth factor and cytokine skin cream for the treatment of skin rejuvenation. J Cosmet Laser Ther (2008) 0.90
Ablative skin resurfacing. Curr Probl Dermatol (2011) 0.90
Complications from injectable polyacrylamide gel, a new nonbiodegradable soft tissue filler. Dermatol Surg (2004) 0.90
Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduct J (2008) 0.90
Clinical comparison of four hair removal lasers and light sources. J Cosmet Laser Ther (2006) 0.90
Recipients of blood or blood products "at vCJD risk". BMJ (2004) 0.89
Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg (2013) 0.89
Use of phosphatidylcholine for the correction of lower lid bulging due to prominent fat pads. J Cosmet Laser Ther (2006) 0.89
Vascular-specific laser wavelength for the treatment of facial telangiectasias. J Drugs Dermatol (2009) 0.89
Calcium hydroxylapatite for facial rejuvenation. Semin Cutan Med Surg (2006) 0.87
Radiofrequency in Cosmetic Dermatology: An Update. J Drugs Dermatol (2015) 0.87
The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol (2009) 0.86
Supplemental tube feeding does not mitigate weight loss in infants with shunt-dependent single-ventricle physiology. Pediatr Cardiol (2013) 0.86
Recent advances in laser dermatology. J Cosmet Laser Ther (2009) 0.86
308-nm Excimer laser treatment of mature hypopigmented striae. Dermatol Surg (2003) 0.85
Prevalence of deficient retro-aortic rim and its effects on outcomes in device closure of atrial septal defects. Pediatr Cardiol (2014) 0.85
Nonablative facial remodeling: erythema reduction and histologic evidence of new collagen formation using a 300-microsecond 1064-nm Nd:YAG laser. Arch Dermatol (2004) 0.85
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol (2012) 0.84
A review of sutures and other skin closure materials. J Cosmet Laser Ther (2010) 0.84
Treatment of melasma with low fluence, large spot size, 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser for the treatment of melasma in Fitzpatrick skin types II-IV. J Cosmet Laser Ther (2011) 0.83
Assessment of safety and efficacy of a bipolar fractionated radiofrequency device in the treatment of photodamaged skin. J Cosmet Laser Ther (2012) 0.83
Controlled volumetric heating of subcutaneous adipose tissue using a novel radiofrequency technology. Lasers Surg Med (2009) 0.83
Trends in the incidence of HIV in Scotland, 1988-2009. Sex Transm Infect (2011) 0.83
Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. Vaccine (2004) 0.82
Evaluation of a new super-long-pulsed 810 nm diode laser for the removal of unwanted hair: the concept of thermal damage time. Dermatol Surg (2002) 0.82
Electrosurgical resurfacing: a clinical, histologic, and electron microscopic evaluation. Lasers Surg Med (2003) 0.82
Millisecond 1064-nm neodymium:YAG laser treatment of facial telangiectases. Dermatol Surg (2003) 0.82
Suture material in cosmetic cutaneous surgery. J Cosmet Laser Ther (2007) 0.81
Digital photography, confidentiality, and teledermatology. Arch Dermatol (2004) 0.81
Like-with-like comparisons? Lancet (2010) 0.81
Laser hair removal pearls. J Cosmet Laser Ther (2008) 0.81
The benefits and harms of breast cancer screening. Lancet (2013) 0.81
Safety and efficacy of fractional bipolar radiofrequency treatment in Fitzpatrick skin types V-VI. J Cosmet Laser Ther (2012) 0.80
Counting the dead: properly and promptly. Lancet (2013) 0.80
Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg (2010) 0.80
Novel hyaluronic acid dermal filler: dermal gel extra physical properties and clinical outcomes. Dermatol Surg (2010) 0.80
Multicenter study comparing shunt type in the norwood procedure for single-ventricle lesions: three-dimensional echocardiographic analysis. Circ Cardiovasc Imaging (2013) 0.80
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology (2013) 0.79
Benign pigmented lesions. Curr Probl Dermatol (2011) 0.79
Hospitalisation for an alcohol-related cause among injecting drug users in Scotland: increased risk following diagnosis with hepatitis C infection. Int J Drug Policy (2010) 0.79
A statistical perspective on the design of drug-court studies. Eval Rev (2009) 0.79
Nonablative dermal remodeling: does it really work? Arch Dermatol (2002) 0.79
Energy-Based Devices in Treatment of Acne Vulgaris. Dermatol Surg (2016) 0.79
A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. J Clin Virol (2013) 0.79
Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. Int J Drug Policy (2012) 0.78